You are here

Nanoparticle-based vaccines against flaviviruses

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI078649-01A1
Agency Tracking Number: AI078649
Amount: $591,408.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2007-2
Timeline
Solicitation Year: 2008
Award Year: 2008
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
BOX 8175
NEW HAVEN, CT 06530
United States
DUNS: 142406110
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 () -
Business Contact
Phone: (203) 393-9439
Email: mmattessich@L2Dx.com
Research Institution
N/A
Abstract

DESCRIPTION (provided by applicant): The objective of this proposal is to develop nanoparticle-based vaccines against West Nile virus. West Nile virus is an emerging human pathogen and a model for other medically important flaviviruses such as dengue viru
s. We and others have shown that a recombinant subunit vaccine consisting of a truncated form of the flaviviral envelope protein can protect animals from otherwise lethal viral challenges. Here we propose to encapsulate recombinant envelope proteins in bio
degradable nanoparticulate cores fabricated from poly(lactic-co-glycolic acid) (PLGA) which have been modified to incorporate immune modulators. Our hypothesis is that this formulation will overcome many weaknesses found in traditional approaches to recomb
inant subunit vaccine development. First, the formulated antigen is expected to be stable at room temperature for extended periods of time. Second, vaccination can occur with a needle-free procedure (oral or intranasal administration). Finally, our results
have shown that immunization with PLGA particles elicits a strong cellular immune response, an essential mechanism to fully eliminate infectious virus. We will synthesize PLGA particles including the envelope protein from West Nile virus. The PLGA particl
es will include varying concentrations of CpG oligonucleotides as an adjuvant. We will then immunize mice, subcutaneously, orally, and intranasally, with the PLGA preparations. We will vary the number of immunizations and the dose of vaccine administered.
The immune response will be characterized in detail. In particular, we will monitor the appearance of virus-neutralizing antibodies as well as virus-specific T cells. We will verify that the immunization is also effective in a distinct strain of mice. Furt
hermore, we will evaluate the stability of the nanoparticles during storage. Finally, mice immunized with our vaccine against West Nile virus will be challenged with an otherwise lethal dose of live virus. We expect to find that vaccinated animals now surv
ive such a challenge. PUBLIC HEALTH RELEVANCE: Flaviviruses such as West Nile virus and dengue virus cause significant human disease and death. We propose to develop a vaccine against diseases caused by these viruses. The vaccine antigen would be a recomb
inant protein derived from the viral envelope, and would be encapsulated in nanoparticles. This would allow us to administer the vaccine orally or intranasally.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government